Their flagship program, GENV-HEM, is a universal gene therapy treatment for hemophilias A and B, which has received support from the National Hemophilia Foundation and orphan drug designation from the FDA. Additionally, GeneVentiv is developing a gene therapy for Hemophilia Arthropathy, a joint disease that affects half of hemophilia patients. Their solutions utilize gene therapy and drug candidates to deliver healthy genes to various cell targets in the body, with a focus on liver-directed diseases such as hemophilia, lysosomal storage disorders, and inherited ocular diseases. Founded in 2020 and based in Raleigh, North Carolina, GeneVentiv aims to provide improved treatments and potentially reduce the cost of treatment for different types of hemophilia.